Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma

Michael A. Thompson, Thomas E. Witzig, Shaji Kumar, Michael M. Timm, Jessica Haug, Rafael Fonseca, Philip R. Greipp, John A. Lust, S. Vincent Rajkumar

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Fingerprint

Dive into the research topics of 'Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma'. Together they form a unique fingerprint.

Medicine & Life Sciences